Seven Bets, and the House Is Winning

Five hundred.

That is the approximate number of innings the Atlanta Braves projected to receive from Spencer Strider, Spencer Schwellenbach, Hurston Waldrep, Joey Wentz, and AJ Smith-Shawver in 2026. Five arms, five development stories, five reasons the front office felt comfortable entering the winter without adding a significant starter from outside the organization. As of today — two days before Opening Day against the Royals at Truist Park — all five are on the injured list. The number of innings they will contribute in the first month of the season is zero.

This is, statistically speaking, not ideal.

I wrote last week that the word if was doing more structural work than any player on this roster. I did not expect the load-bearing collapse to arrive before the first pitch. I wrote Monday about Strider's oblique — his second, the body keeping its meticulous records. But Strider is not the story anymore. He is one line item in a ledger that has grown beyond any single entry.

So let us do the arithmetic.

The subtraction problem begins on the mound and radiates outward. Strider: left oblique strain, IL, no grade disclosed, optimistically late April per ESPN. Schwellenbach: bone spur removal, 60-day IL, no return date per MLB.com. Waldrep: loose body removal, 60-day IL, same uncertainty. Wentz: torn ACL covering first base in spring training, season over per ESPN. Smith-Shawver: Tommy John from June 2025, not expected until 2027 per MLB.com.

Then move to the lineup. Jurickson Profar — the $15 million designated hitter signed to provide middle-of-the-order stability — is suspended 162 games after his second positive PED test in twelve months, per ESPN. He is the sixth player to receive a full-season PED ban since MLB increased the two-time offender penalty in 2014. He forfeits his entire 2026 salary. He is ineligible for the postseason even if the Braves somehow get there.

Ha-Seong Kim — the $20 million shortstop who was supposed to stabilize a position unsettled since Dansby Swanson left after 2022 — tore a tendon in his right middle finger after slipping on ice in South Korea in January. Surgery by Dr. Gary Lourie. Four to five months, per ESPN. Early May at the earliest. Mauricio Dubón, the versatile and defensively gifted utility man, steps in at short.

Seven absences. Five pitchers. One DH. One shortstop. The word triage is not editorializing. It is clinical description.

The rotation that opens Friday against Kansas City will be Chris Sale, Reynaldo López, Grant Holmes, Bryce Elder, and a fifth starter still to be named, per Battery Power. The imagined January rotation — Sale, Strider, López, Schwellenbach, Waldrep — had a combined projected workload north of 800 innings. What actually takes the mound might manage 650, with wider variance and a lower ceiling.

Sale remains the anchor: a Cy Young winner in 2024 (18-3, 2.38 ERA per Baseball Reference), still effective in a rib-shortened 2025 (2.58 ERA, 165 K in 125.2 IP per ESPN). He turns thirty-seven on March 30. López is durable. Holmes posted a 2.73 ERA over a 62.2-inning stretch last season, though his 3.63 FIP suggests he was catching some luck per FanGraphs. Elder fills a slot. These are functional arms. They are not the rotation of a team that expected to contend for a division title.

Dex dropped his win projection from 95 to 88 overnight. His gut has served him well before, but the question deserves more precision. FanGraphs had the Braves at approximately 90 wins before the injury cascade. Subtract the rotation downgrade — somewhere between 3 and 5 wins of pitching value lost over a full season, depending on how long the absences last and how the replacements perform. Factor in Profar's bat (roughly 2 WAR projected) vanishing entirely and Kim's absence through May. The math lands in an uncomfortable range: 83 to 87 wins, depending on which version of the remaining roster shows up. Dex's 88 is not pessimistic. It might be the ceiling.

There is light, and it is not entirely false light. Drake Baldwin, the reigning NL Rookie of the Year (.274/19 HR/80 RBI in 2025, per Baseball Reference), hit .333 this spring with an 87% hard-hit rate that leads all of baseball, per MLB.com. Twenty of his twenty-three balls in play left the bat at 95 mph or harder. Twelve exceeded 100 mph. Walt Weiss put it simply: "He just barrels baseballs one after another." If the sophomore leap is real — and the spring data suggests it might be — Baldwin is an MVP-caliber presence behind the plate.

Didier Fuentes, the twenty-year-old right-hander from Tolú, Colombia, made the Opening Day roster after a spring that defied description: 1 earned run, 18 strikeouts, 1 walk, and just 2 hits allowed across 13.2 innings, per MLB Trade Rumors. His fastball touches 99 mph. His 2025 debut — 13.85 ERA across 4 starts — is the necessary asterisk. He will start in the bullpen. Spring and September are different currencies, and Fuentes has not yet demonstrated he can exchange one for the other.

The bullpen back end — Raisel Iglesias and Robert Suárez — looked sharp in the spring finale, a 3-2 win over the Rays. That is not nothing.

The Braves have always been a franchise defined by pitching. Maddux, Glavine, Smoltz — the template was set three decades ago, and the development pipeline that produced Strider, Schwellenbach, Waldrep, Fuentes, and Smith-Shawver is the institutional descendant of that tradition. The pipeline works. It keeps producing electric arms. Those arms keep breaking. There is a paradox in there that the organization will eventually need to reckon with: the system that is the franchise's deepest strength is also the source of its most persistent vulnerability.

I wrote four days ago that the Braves go exactly as far as Strider's arm takes them. That thesis needs revision. The health bet was not one bet. It was seven. And before the umpire calls the first strike of 2026, the Braves have already lost at least four of them.

Baseball has a long memory, and 162 games is enough time for rosters to heal, for prospects to arrive, for the math to shift. But it is also enough time for the damage to compound. The Braves will spend the first month of this season answering a question they were not supposed to face until September: is what remains enough?

The numbers will tell us. They always do. But not yet.